Cidara Cuts Workforce to Prioritize CD388 for Influenza Prevention
Cidara's Workforce Reduction
Cidara (CDTX) announced a workforce reduction of approximately 30% in a strategic pivot to emphasize its drug-Fc conjugate candidate, CD388. This decision aims to channel resources effectively towards developing an innovative treatment option for influenza A and B.
Implications of Focusing on CD388
The prioritization of CD388 reflects Cidara's commitment to advancing healthcare technology and addressing significant public health challenges posed by influenza. The restructuring showcases their dedication to delivering impactful pharmaceutical solutions that could transform patient care in the future.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.